- Home
- DYAI vs RNTX Comparison
DYAI vs RNTX Comparison
Compare DYAI & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYAI | RNTX |
|---|---|---|
| Founded | 1979 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 35.5M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | DYAI | RNTX |
|---|---|---|
| Price | $0.96 | $1.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 496.0K | 236.3K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,342,195.00 | N/A |
| Revenue This Year | $12.52 | N/A |
| Revenue Next Year | $92.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $1.04 |
| 52 Week High | $2.14 | $3.50 |
Technical Indicators
Market Signals| Indicator | DYAI | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 39.35 |
| Support Level | $0.80 | $1.28 |
| Resistance Level | $1.04 | $1.47 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 63.14 | 8.33 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.